

Supplemental Table for:
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: from Personalized Medicine to Public Health
Elaine Chang et al.

Supplementary material (online only)

Table. Companion* and complementary# *in vitro* diagnostic (IVD) PD-L1 assays

<p style="text-align: center;">Dako 28-8</p> <p>Advanced urothelial</p> <ul style="list-style-type: none"> nivolumab 2nd L-M PD-L1+ TC ≥ 1% <p>HNSCC</p> <ul style="list-style-type: none"> nivolumab 2nd L-M PD-L1+ TC ≥ 1%, 5%, 10% <p>NSCLC</p> <ul style="list-style-type: none"> nivolumab + ipilimumab 1st L PD-L1+ TC ≥ 1% nivolumab 2nd L-M PD-L1+ TC ≥ 1%, 5%, 10% 	<p style="text-align: center;">Dako 22C3</p> <p>Advanced urothelial</p> <ul style="list-style-type: none"> pembrolizumab cisplatin-ineligible 1st L-M, CPS ≥ 10 <p>Cervical</p> <ul style="list-style-type: none"> pembrolizumab 2nd L-M, CPS ≥ 1 <p>NSCLC:</p> <ul style="list-style-type: none"> pembrolizumab 1st L-M, TPS ≥ 1% pembrolizumab 2nd L-M, TPS ≥ 1% <p>Esophageal SCC</p> <ul style="list-style-type: none"> pembrolizumab 2nd L-M, CPS ≥ 10 <p>Gastric/GEJ adeno</p> <ul style="list-style-type: none"> pembrolizumab 2nd L-M, CPS ≥ 10 <p>HNSCC</p> <ul style="list-style-type: none"> pembrolizumab 1st L-M, CPS ≥ 1
<p style="text-align: center;">Ventana SP263</p> <p>Bladder</p> <ul style="list-style-type: none"> durvalumab 2nd L-M TC ≥ 25%; or ICP > 1% with PD-L1+ IC ≥ 25%; or ICP = 1% with PD-L1+ IC = 100% 	<p style="text-align: center;">Ventana SP142</p> <p>Bladder:</p> <ul style="list-style-type: none"> atezolizumab cisplatin-ineligible 1st L-M ≥ 50% TC or ≥ 10% IC <p>Breast:</p> <ul style="list-style-type: none"> atezolizumab + paclitaxel protein-bound 1st L-M ≥ 1% IC <p>NSCLC:</p> <ul style="list-style-type: none"> atezolizumab 1st L-M, TC ≥ 50% or IC ≥ 10% atezolizumab 2nd L-M ≥ 1% TC or ≥ 1% IC

* Provides information that is essential for the safe and effective use of a corresponding drug or biological product.

Provides information to support the use of a drug, biological product, or a class of agents.

Intended uses in italics denote complementary IVDs. Regular font denotes companion IVDs.

Tumor cell staining: tumor cells (TC), tumor proportion score (TPS)

Immune cell staining: immune cells (IC), immune cells present (ICP)

Both: combined positive score (CPS)